Trial record 6 of 9 for:
"Hematemesis"
Capsule Endoscopy for Hemorrhage in the Emergency Room (CHEER)
This study is not yet open for participant recruitment.
Verified December 2016 by George Washington University
Sponsor:
George Washington University
Collaborator:
Medtronic
Information provided by (Responsible Party):
George Washington University
ClinicalTrials.gov Identifier:
NCT01371591
First received: June 9, 2011
Last updated: December 16, 2016
Last verified: December 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The researcher's primary hypothesis is that VCE allows for safe outpatient management of ED patients with suspected upper GI hemorrhage. A prospective multicenter randomized control trial was designed to investigate the safety of this approach.
| Condition | Intervention |
|---|---|
| Melena Hematemesis Peptic Ulcer Hemorrhage Variceal Hemorrhage | Device: Experimental Capsule Endoscopy Device: Standard of Care plus EGD |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Pilot Study to Investigate the Use of Wireless Capsule Endoscopy for Emergency Department Patients With Suspected Acute Upper Gastrointestinal Bleeding |
Resource links provided by NLM:
Further study details as provided by George Washington University:
Primary Outcome Measures:
- to test whether risk stratification ED Video Capsule Endoscopy (VCE) in the ER leads to decreased need for hospitalization [ Time Frame: 24 hours ]Our primary question is whether VCE can diagnose UGIH in the acute setting.is to test whether ED Video Capsule Endoscopy (VCE) in the ER is able to safely discharge low risk patients for outpatient evaluation
Secondary Outcome Measures:
- to estimate the sensitivity and specificity of VCE compared to subsequent EGD [ Time Frame: 72 ]to estimate the sensitivity and specificity of VCE compared to subsequent EGD in the detection of serious bleeding lesions in the upper gastrointestinal (GI) tract.
| Estimated Enrollment: | 100 |
| Study Start Date: | March 2017 |
| Estimated Study Completion Date: | August 2018 |
| Estimated Primary Completion Date: | March 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Experimental Capsule Endoscopy
Patient will be monitored for a minimum of 4 hours. VCE will be read by site PI or co-PI and by site GI doc. Repeat CBC at q4 hours. Stable BP and pulse for 4 plus hours -> discharge home with follow up EGD within 3 days.
|
Device: Experimental Capsule Endoscopy |
|
Placebo Comparator: Standard of Care plus EGD
VCE video will be archived and read at a later date. Pt will be admitted. VCE will not be used for clinical decisions. Same day or next day (<24 hour) Endoscopic examination of the upper GI tract will be offered to all patients within 24 hours, and hemostasis therapy was applied as necessary |
Device: Standard of Care plus EGD |
Detailed Description:
The typical primary care, urgent care or emergency care provider is unable to evaluate common and serious conditions of the gastrointestinal tract such as a bleeding peptic ulcer. As such, more than 80% of patients who present to US ED's with suspected bleeding in their upper GI tract require hospitalization, procedural sedation by an anesthesiologist, and a traditional tube-based upper endoscopy by a gastroenterologist. While this traditional process is safe and effective, it is not efficient for our low-risk patients and not timely for our high-risk patients. The opportunity to bring Video Capsule Endoscopy to the front-lines of US medical care will revolutionize how we manage upper GI bleeding and shed light on critical diseases that have heretofore been hidden from most providers. This trial is an important step toward demonstrating that VCE is a safe and effective tool to risk-stratify upper GI bleeding and improve quality of emergency care for all patients.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Subject Inclusion Criteria
1. Individuals aged ≥ 18 years presenting to the Emergency Department with acute, overt UGIB defined as bloody emesis and/or coffee ground vomiting and/or melena within the previous 48 hours.
Subject Exclusion Criteria
- Upper GI Bleed with hemodynamic shock (BP<90mmHg and pulse>120 per minute)
- Active hematemesis
- Known history of gastric cancer
- Known history of gastric or esophageal varices
- GI surgery within the last 6 months
- Dysphagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or perforation
- Gastroparesis, Gastric outlet obstruction, Crohn's disease, past UGI tract surgery (e.g., Bilroth I or II, esophagectomy, gastrectomy, bariatric procedure)
- Other contraindications to VCE per manufacturer (Medtronic)
- Pregnancy/ lactation
- Prisoner
- Altered mental status (e.g., hepatic encephalopathy) that limits the ability to swallow a capsule
- Expected to have Magnetic Resonance Imaging examination within 7 days.
- On medications that may coat the upper GI tract such as antacids or sucralfate or Maalox.
- Patient either refuses or is unable to get traditional EGD.
- Patient does not have reliable contact information - no phone, no permanent address.
- Patient refuses / chooses to withdraw (at any time) / unable to provide written consent.
- Non-English speaker
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371591
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371591
Locations
| United States, District of Columbia | |
| George Washington University Hospital | Recruiting |
| Washington, District of Columbia, United States, 20037 | |
| Contact: Donna Embersit 202-741-2798 dembersit@mfa.gwu.edu | |
Sponsors and Collaborators
George Washington University
Medtronic
Investigators
| Principal Investigator: | Andrew C Meltzer, MD | George Washington University |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | George Washington University |
| ClinicalTrials.gov Identifier: | NCT01371591 History of Changes |
| Other Study ID Numbers: |
GWIRB#: 080933 |
| Study First Received: | June 9, 2011 |
| Last Updated: | December 16, 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
Keywords provided by George Washington University:
|
hematemesis Bleeding gastrointestinal hemorrhage ulcer varix varices |
ulcers GI stomach esophagus duodenum melena coffee-ground |
Additional relevant MeSH terms:
|
Hematemesis Emergencies Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Melena Disease Attributes Pathologic Processes Duodenal Diseases |
Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Gastrointestinal Hemorrhage Vomiting Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on July 14, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
